Table 2.

Comparing the Mean Scores of Pain Severity Before and After the Intervention Between Both Groups

	Vitamin D 5000 IU + Standard Treatment (n=34)	Standard Treatment (n=34)	Overall (n=68)	p-valuea
Visual analog scale (0–10)
Baseline	5.74 ± 2.16	5.46 ± 2.13	5.60 ± 2.13	0.560
Week 4	3.76 ± 2.32	3.81 ± 2.47	3.79 ± 2.38	0.946
Week 8	2.39 ± 2.09	3.09 ± 2.33	2.74 ± 2.22	0.221
Changes from baseline to week 8	−3.34 ± 2.03	−2.37 ± 2.2	−2.85 ± 2.16	0.044*
p-valueb	<0.001*	<0.001*	<0.001*
Burning pain (0–100)
Baseline	11.76 ± 23.8	17.06 ± 25.88	14.41 ± 24.82	0.384
Week 4	4.18 ± 11.84	9.41 ± 17.22	6.76 ± 14.91	0.189
Week 8	1.76 ± 7.16	6.18 ± 13.93	3.97 ± 11.21	0.046*
Changes from baseline to week 8	−10 ± 20.15	−10.89 ± 25.51	−10.44 ± 22.82	0.859
p-value	0.007*	0.023*	0.001*
Electric shocks pain (0–100)
Baseline	10.29 ± 21.39	22.35 ± 27.64	16.32 ± 25.27	0.057
Week 4	6.47 ± 17.21	12.35 ± 20.75	9.41 ± 19.15	0.110
Week 8	4.71 ± 13.54	6.76 ± 13.64	5.74 ± 13.63	0.482
Changes from baseline to week 8	−5.59 ± 12.36	−15.59 ± 23.77	−10.59 ± 19.46	0.070
p-valueb	0.011*	0.001*	<0.001*
Tingling (0–100)
Baseline	30.88 ± 29.27	36.18 ± 30.85	33.53 ± 29.96	0.483
Week 4	17.94 ± 22.8	25.29 ± 27.55	21.62 ± 25.37	0.242
Week 8	10.59 ± 18.9	20.29 ± 26.91	15.44 ± 23.59	0.096
Changes from baseline to week 8	−20.29 ± 23.29	−15.88 ± 21.62	−18.09 ± 22.41	0.415
p-valueb	<0.001*	<0.001*	<0.001*
Numbness (0–100)
Baseline	43.53 ± 31.13	41.76 ± 25.76	42.65 ± 28.37	0.719
Week 4	29.41 ± 29.23	30.88 ± 27.34	30.15 ± 27.34	0.750
Week 8	20.59 ± 25.93	26.47 ± 26.73	23.53 ± 26.30	0.257
Changes from baseline to week 8	−22.94 ± 24.93	−15.29 ± 18.13	−19.12 ± 21.97	0.373
p-valueb	<0.001*	<0.001*	<0.001*

Notes: Data are presented as mean ± standard deviation (SD); ^aComparison between the experimental and control group; ^bComparison within-group under the same conditions; *p-value is statistically significant.